Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Similar documents
1

What is Osteoporosis?

John J. Wolf, DO Family Medicine

Page 1

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Prevention of Osteoporotic Hip Fracture

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

Osteoporosis/Fracture Prevention

Osteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Closing the Care Gap in Osteoporosis ICE Conference 2015

New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS

Osteoporosis. Treatment of a Silently Developing Disease

Osteoporosis. Overview

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

Osteoporosis Agents Drug Class Prior Authorization Protocol

Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Management of postmenopausal osteoporosis

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

AACE/ACE Osteoporosis Treatment Decision Tool

Osteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists

Update on Osteoporosis 2016

Osteoporosis Clinical Guideline. Rheumatology January 2017

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Bisphosphonates. Making intelligent drug choices

New Developments in Osteoporosis: Screening, Prevention and Treatment

BREAST CANCER AND BONE HEALTH

COURSE OUTLINE - Module I

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Trends in Glucocorticoid-Induced Osteoporosis Management Among Seniors in Ontario,

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Osteoporosis challenges

Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital

Chau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences

Men and Osteoporosis So you think that it can t happen to you

OSTEOPOROSIS MEDICINES

Clinician s Guide to Prevention and Treatment of Osteoporosis

Pathway from Fracture or Risk Factor to Treatment

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist

Cortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT

Current and Emerging Strategies for Osteoporosis

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Hot Topics in Osteoporosis and Fracture Prevention

Osteoporosis. Osteoporosis ADD PICTURE

New Osteoporosis Guidelines: What you and your health provider need to know QUESTION & ANSWER

Download slides:

Understanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.

Building Bone Density-Research Issues

All about. Osteoporosis

Assessment and Treatment of Osteoporosis Professor T.Masud

The Osteoporosis Center at St. Luke s Hospital

OSTEOPOROSIS IN INDONESIA

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

SOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE

Bone Densitometry Pathway

Osteoporosis. Definition

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

OSTEOPOROSIS ASSESSMENT CENTER

Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation

Talking to patients with osteoporosis about initiating therapy

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Keeping old bones from breaking: The diagnosis, prevention, and treatment of osteoporosis

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC

Summary. Background. Diagnosis

Vasu Pai FRACS, Nat Board, MCh, M.S

Updates in Osteoporosis

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Medical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018.

Osteoporosis. Information leaflet. This information is also available on request in other formats by phoning

Acknowledgement of Privacy Statement, Authorization and Assignments of Benefits. Release of Medical Information, Appointments and Prescriptions

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

COPING A newsletter from COPN December 23, 2010 Remember: You can live well with osteoporosis!

Osteoporosis Management

Fracture=Bone Attack:

BONIVA (ibandronate sodium)

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

Monitoring Osteoporosis Therapy

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C

Bone Health for Women: Current Research, Initiatives and Recommendations

Focusing on the Patient: Diagnosis and Management of Osteoporosis

Osteoporosis. Skeletal System

4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017

SpongeBone Menopants*

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Practical Management Of Osteoporosis

Osteoporosis and Bone Health. Heather Schickedanz, MD Geriatric Knowledge Network, 08/10/16

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

Bisphosphonate treatment break

Session 4: New Evidence-Based Clinical Prac ce Guidelines B: Management of Osteoporosis in Post-Menopausal Women 4:15pm - 5:15pm

Using the FRAX Tool. Osteoporosis Definition

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Major Recommendations Recommendations apply to postmenopausal women and men age 50 and older.

Beyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO

Transcription:

Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011

Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician

Definition of Osteoporosis Bone disorder characterized by low bone strength resulting in bone fragility and an increased risk of fractures Bone strength depends upon two features: Bone density Bone quality Occurs when the rate of bone loss exceeds the rate of bone formation over an extended period

The bone remodeling cycle. Derived from Roodman GD. N Engl J Med. 2004;350:1655-1664.

Assessment for Osteoporosis Who should be assessed? Women and men over 50 to identify those at high risk Anyone over 50 who has experienced a fragility fracture How is the Assessment Done? Detailed history to identify risk factors for low BMD, future fractures and falls: Prior fragility fracture Parental hip fracture Glucocorticoid use Current smoking High alcohol intake (3 or more drinks per day)

Assessment for Osteoporosis Rheumatoid arthritis Inquire about falls in past 3 months Inquire about gait and balance Physical examination Measure weight Screening for vertebral fractures: Measure height annually Measure rib to pelvis distance Measure occiput-to to-wall distance Spinal x-ray x indicated if there is evidence of vertebral fracture Assess fall risk by using Get-Up Up-and-Go Test

(CAROC) CAROC) - Canadian Association of Radiologists and Osteoporosis Canada Other factors in addition to (hip) BMD results are used to determine 10-year fracture risk These factors are age, sex, fracture history and glucocorticoid use FRAX Tools for Assessment In 2008, the World Health Organization (WHO) launched FRAX, a web-based based fracture risk assessment tool. In 2010 Canadian data were added. In addition to femoral neck (hip) BMD, age, gender, fracture history and steroid use, FRAX also takes into account other risk factors to calculate the absolute 10-year risk of a hip fracture or other major osteoporotic fracture (spine, forearm, upper arm).

Goal of drug treatment: Prevention of osteoporosis in high risk people Prevention of further bone loss Rebuild healthy bone Fracture prevention Fall prevention

Medications Associated with Increased Risk of Osteoporosis Oral steroids (e.g. Prednisone, Dexamethasone) Depo-Provera Anti-seizure drugs (e.g. Phenytoin, Carbamazepine, Phenobarbital) Cyclosporin Lithium SSRI s s (implicated) Anti-estrogen drugs (e.g.?tamoxifen, Anastrozole, Letrozole, Exemestane)

Disorders Associated with an Increased Risk of Osteoporosis Irritable Bowel Syndrome Celiac disease Rheumatoid arthritis Ankylosing Spondylitis Lymphoma Leukemia Pernicious Anemia Multiple Sclerosis Breast Cancer...

Drug categories Bisphosphonates Etidronate/Didronel tm Alendronate/ Fosamax tm Risedronate/ Actonel tm Zoledronic acid /Aclasta Ibandronate/Boniva Denosumab SERMs Raloxifene - Evista tm Calcitonin /Miacalcin tm HRT PTH (Forteo) Fluoride Vitamin D Calcium Strontium ranelate/ Protos tm

Medication activity Bone resorption inhibitors Bisphosphonates SERM s HRT Calcitonin Bone formation stimulators Parathyroid hormone Fluoride Monoclonal antibody

Bisphosphonates Bind to bone and slow down bone-eroding eroding cells (osteoclasts) Alendronate (Fosamax ), Risedronate (Actonel ), Etidronate (Didrocal ) Pamidronate (Aredia ), Zoledronate (Zometa )Zoledronic Acid (Aclasta) Can be used for both prevention and treatment of osteoporosis

Bisphosphonates: Mechanism of Action Roger M. Bone 1999,24, 739

Treatment Controversies Jaw Necrosis pamidronate and zolendronate IV in patients treated for cancer and not osteoporosis; This side effect is rare, but a concern nevertheless since it is thought to affect all bisphosphonates. Rare reports have been described with alendronate Text (Fosamax ) ) or risedronate (Actonel ). Increased Risk of Atypical Fractures long-term alendronate use further studies needed to establish whether a clear association exists thigh fracture associated with bisphosphonate use is extremely rare, on the other hand, fractures due to osteoporosis are extremely common

Lifestyle Changes Increase physical activity (weight-bearing exercise) Reduce/eliminate tobacco Reduce/eliminate caffeine intake Reduce/eliminate alcohol intake Minimize risk of falling ENSURE ADEQUATE CALCIUM AND VITAMIN D INTAKE...

Diet and Bone Health Calcium: Bone is really a bank,, or place where the body can store and retrieve calcium - the mineral that makes bone hard. Vitamin D: Is needed to make sure the body can absorb calcium from food.

Age Calcium Needs 1-3 yrs 500 mg 4-8 800 mg 9-18 1300 mg 19-30 1000 mg 31-50 1000 mg 51+ 1200 mg Nat l l Academy of Sci 1997 OSC 2001

Vitamin D House bound elderly at greatest risk of deficiency Sun exposure is not enough to replace ingested Recommendations by age: AGE DAILY INTAKE 19 to 50 400-1000 IU 50 + 800-2000 IU

Pharmacy Technicians role Patient education Know required amounts of calcium and Vitamin D at various stages in life Know correct amounts of Ca not more than 500mg at one time Watch for patients on any of the potential bone- loss medications and advise accordingly Be attentive to pt s s complaining of falling or dizziness and refer patient to the pharmacist pt s s refusing to take Ca supplements due to media reports of it causing heart attacks should be referred to the pharmacist